155 related articles for article (PubMed ID: 36223973)
1. Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile.
Singh N; Singh R; Decker B; Robins D; Vidal G
BMJ Case Rep; 2022 Oct; 15(10):. PubMed ID: 36223973
[TBL] [Abstract][Full Text] [Related]
2. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
3. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
[TBL] [Abstract][Full Text] [Related]
4. Problematic breast tumors reassessed in light of novel molecular data.
Pareja F; Weigelt B; Reis-Filho JS
Mod Pathol; 2021 Jan; 34(Suppl 1):38-47. PubMed ID: 33024304
[TBL] [Abstract][Full Text] [Related]
5. Cytological and molecular characterization of secretory breast carcinoma.
Carretero-Barrio I; Santón A; Caniego Casas T; López Miranda E; Reguero-Callejas ME; Pérez-Mies B; Benito A; Palacios J
Diagn Cytopathol; 2022 Jul; 50(7):E174-E180. PubMed ID: 35156343
[TBL] [Abstract][Full Text] [Related]
6. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.
Krings G; Joseph NM; Bean GR; Solomon D; Onodera C; Talevich E; Yeh I; Grenert JP; Hosfield E; Crawford ED; Jordan RC; van Zante A; Zaloudek C; Shin SJ; Chen YY
Mod Pathol; 2017 Aug; 30(8):1086-1099. PubMed ID: 28548128
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
[TBL] [Abstract][Full Text] [Related]
9. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.
Del Castillo M; Chibon F; Arnould L; Croce S; Ribeiro A; Perot G; Hostein I; Geha S; Bozon C; Garnier A; Lae M; Vincent-Salomon A; MacGrogan G
Am J Surg Pathol; 2015 Nov; 39(11):1458-67. PubMed ID: 26291510
[TBL] [Abstract][Full Text] [Related]
10. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.
Makretsov N; He M; Hayes M; Chia S; Horsman DE; Sorensen PH; Huntsman DG
Genes Chromosomes Cancer; 2004 Jun; 40(2):152-7. PubMed ID: 15101049
[TBL] [Abstract][Full Text] [Related]
11. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
[TBL] [Abstract][Full Text] [Related]
12. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.
Laé M; Fréneaux P; Sastre-Garau X; Chouchane O; Sigal-Zafrani B; Vincent-Salomon A
Mod Pathol; 2009 Feb; 22(2):291-8. PubMed ID: 19011601
[TBL] [Abstract][Full Text] [Related]
13. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
[TBL] [Abstract][Full Text] [Related]
14. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
[TBL] [Abstract][Full Text] [Related]
15. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
Bell D; Ferrarotto R; Liang L; Goepfert RP; Li J; Ning J; Broaddus R; Weber RS; El-Naggar AK
Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
[TBL] [Abstract][Full Text] [Related]
16. Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.
Landman Y; Ilouze M; Wein S; Neiman V; Yerushalmi R; Yakimov M; Ku N; Schrock AB; Ali S; Peled N
Clin Breast Cancer; 2018 Jun; 18(3):e267-e270. PubMed ID: 29233640
[No Abstract] [Full Text] [Related]
17. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
18. TRK inhibitor in a patient with metastatic triple-negative breast cancer and
Medford AJ; Oshry L; Boyraz B; Kiedrowski L; Menshikova S; Butusova A; Dai CS; Gogakos T; Keenan JC; Occhiogrosso RH; Ryan P; Lennerz JK; Spring LM; Moy B; Ellisen LW; Bardia A
Ther Adv Med Oncol; 2023; 15():17588359231152844. PubMed ID: 36743521
[TBL] [Abstract][Full Text] [Related]
19. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
O'Reilly EM; Hechtman JF
Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
[TBL] [Abstract][Full Text] [Related]
20. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
